Topas Therapeutics Announces Presentation of Phase 2a Data for TPM502 in Celiac Disease at Digestive Disease Week® 2025 in San Diego

Press Releases Hamburg, Germany, April 24, 2025 – Topas Therapeutics today announced that it will present clinical Phase 2a data on its lead candidate, TPM502, in celiac disease patients at the upcoming Digestive Disease Week® (DDW) 2025, held from May 3–6, 2025, in San Diego, CA. TPM502 comprises a tolerizing nanoparticle mixture that carries the crucial gluten epitopes for HLA-DQ2.5, present in most celiac disease patients. In October of last year, the company announced positive topline results from its Phase 2a trial evaluating TPM502, showing persistent, antigen-specific tolerogenic effects in patients with celiac disease. The abstract was selected for presentation in two sessions at DDW. Further details are listed below and available for registered attendees on the DDW conference website . Session Title: American Gastroenterological Association (AGA) Clinical Science Plenary Session Date & Time: Monday, May 5 th , 08:00 – 9:30 am PDT Abstract Title: 621 : Safety, Tolerability and Pharmacodynamic Effects of TPM502, a Mixture of Tolerizing Nanoparticles for Treatment of Celiac Disease (CeD) Presenter: Knut Lundin, MD, PhD, Principal Investigator of the Phase 2a study and Professor and Head of Clinical Education at the Institute of Clinical Medicine, University of Oslo Session Title: AGA Presidential Plenary: AGA at its Best and the Best of AGA Session Date & Time: Monday, May 5 th , 10:00 – 11:30 am PDT Abstract Title: Sp832: Safety, Tolerability and Pharmacodynamic Effects of TPM502, a Mixture of Tolerizing Nanoparticles for Treatment of Celiac Disease (CeD) Presenter: Knut Lundin, MD, PhD, Principal Investigator of the Phase 2a study and Professor and Head of Clinical Education at the Institute of Clinical Medicine, University of Oslo About Topas Therapeutics Topas Therapeutics, a clinical stage biotech company, is advancing a highly differentiated and versatile approach to establish immune tolerance in autoimmune and immune-mediated diseases. Our proprietary Topas Platform, comprising antigen-coupled nanoparticles, targets liver sinusoidal endothelial cells to drive T cells toward tolerance. The topline readout from our Phase 2a clinical trial in celiac disease validates the power of this new drug modality and its potential to address a broad range of immune-mediated indications, positioning us to deliver significant therapeutic benefits to patients. For further information: https://topas-therapeutics.com/ Contacts: Topas Therapeutics GmbH Contacts: Topas Therapeutics Alex Marshall PhD MBA Chief Business Officer [email protected] Trophic Communications Eva Mulder Phone: +31 65 2331 579 [email protected]

The release as fetched from its publisher. topas-therapeutics.com ↗